Advance Partnerships

HEALTHCARE INDUSTRY CAPITALISING ON SUCCESSFUL ACADEMIC RESEARCH

  • ADVANCE PARTNERSHIPS - The ecosystem for Pharma, Biotech, MedTECH and Cosmetics Companies  looking for latest discoveries & scientific collaboration in Drug Discovery & Therapeutic candidates, Diagnostics, R&D technologies &  MedTECH; and for Hospitals, Academic Centers, Universities and Scientific Institutes interested in Industry partners for their healthcare discoveries & expertise
  • Our experimental data show that, following treatment of SCs with chemotherapeutic drugs, it was possible to observe a significant reduction in hydroxymethylcytosine and a significant reduction in the gene expression of GDNF and of the GDNF protein compared to untreated SCs. Furthermore, a protective effect of EPA was demonstrated at a concentration of 100 μM on SCs treated at the highest dose of cisplatin (3.33 μM). This effect was demonstrated both in terms of gene and protein expression of Sertolian GDNF, and in terms of gene expression and secretion of AMH and inhibin B as specific markers of Sertolian functionality. In particular, Sertolian GDNF was surprisingly recovered compared to the control group and AMH and inhibin B reached values comparable to those of the control group. Current phase & next steps We have completed in vitro PC testing and are ready for in-vivo PC phase. Here at University of
  • This invention relates to the use of anakinra to produce an inhalable dry powder for the treatment of pathological inflammation in patients with cystic fibrosis (CF). Persistent inflammation and infection lead to permanent structural damage of the CF airways, impaired lung function, and eventually to respiratory failure and death. Recent studies have suggested a link between neutrophilic inflammation, mucus obstruction and the IL-1R signalling pathway. Therefore, targeting IL-1R signalling could be an effective strategy to prevent structural lung damage. Such conditions could be efficiently rescued by anakinra, a recombinant non-glycosylated form of the endogenous IL-1R antagonist. Anakinra (Kineret®) is administered subcutaneously for the treatment of rheumatoid arthritis, cryopyrin-associated periodic syndromes, and the systemic-onset juvenile idiopathic arthritis. Owing to low compliance and side effects, the current form is not suitable for chronic treatments, such as in CF. Therefore, turning anakinra into an inhalable dry powder can enhance efficacy, stability, and compliance, reduce side effects allowing repurposing of the drug in CF therapy. TECHNOLOGY/INVENTION An inhalable dry powder of anakinra was successfully developed to meet the specific needs of lung drug delivery. The new formulation was investigated in vitro for aerodynamic performances and activity and in vivo for its pharmacological profile, including the pharmacokinetics, treatment schedule, antimicrobial and anti-inflammatory activity and systemic toxicity. The protein was structurally preserved inside the formulation and retained its pharmacological activity in vitro immediately after preparation and over time when stored at ambient conditions. Anakinra when delivered to the lungs showed an improved and extended therapeutic efficacy in CF models in vivo as well as higher potency compared to systemic delivery. Peripheral side effects were significantly reduced and correlated with lower serum levels compared to systemic treatment.
  • The invention relates to oxysterol derivatives PFM037 and PFM046, able to act as antagonists of the Liver X Receptors (LXRs) which can be used alone or in combination with other anti cancer therapies, such as the immune checkpoint inhibitors (CI) or T cell adoptive therapy to treat different cancers, including melanoma, Hodgkin lymphoma, renal, lung, bladder and head and neck cancers. The inventors found that SULT2B1b system manipulation favours the differentiation of Ly6C+ monocytes into Mono-DCs. This pathway is associated with lipidome reprogramming characterized by reduced levels of cellular cholesterol/cholesterol derivatives and glycerophospholipids, and increased levels of polyunsaturated fatty acid precursors of lipid mediators endowed with pro-inflammatory activity. This lipidomic profile was also detected in tumours from mice treated with the new synthetic compounds PFM037 and PFM046, structurally and functionally related to SULT2B1b-derived products. PFM037 contributes to monocyte differentiation and induces effective antitumor responses by interfering with LXR signalling. Moreover, it increases the efficacy of ICIs and T cell adoptive therapy. Finally, by interrogating available scRNA-seq datasets
  • The invention described herein relates to the use of OMEGA-3 polyunsaturated fatty acids (EPA) for the prevention and treatment of male infertility in prepubertal subjects undergoing chemotherapeutic and/or radiotherapeutic treatments for the treatment of neoplasms. Background The chemo- and radiotherapy treatments used in the cure of pre-pubertal subjects affected by neoplastic diseases and serious inflammatory diseases of autoimmune etiology, have high cytotoxicity capable of altering or completely compromising the male gonad, with consequent reduction or loss of endocrine function and fertility. In adult patients, preservation of semen before cancer treatment is currently the only method of preserving future male fertility. Obviously, this technique is not an option for pre-pubertal patients who do not yet produce mature spermatozoa that can be used for routine sperm cryopreservation. The Sertoli cells (SCs), the only somatic cell type in the seminiferous tubules, can be considered the real “director” of spermatogenesis. SCs growth factors, such as glial cell line-derived neurotrophic factor (GDNF), have been identified as the most important upstream factors that regulate spermatogonial stem cells (SSC) germ cell self-renewal and spermatocyte meiosis. DNA methylation, considered as one of the main epigenetic mechanisms, is already known to influence male fertility. It was demonstrated that eicosapentaenoic acid (EPA), a fatty acid with anti-cancer properties, is able to decrease DNA methylation levels through the activation of ten-eleven translocation enzymes proteins (TETs). We report the effects on porcine neonatal SCs “in vitro” of three different chemotherapeutic agents, cisplatin, 4- Hydroperoxycyclophosphamide (40HP) and doxorubicin, commonly administered to pre-pubertal candidates undergoing anti-cancer therapy, and the positive effects of EPA on these gonado-toxic compromised SCs.

Become a member

Contact Us

+44 207 209 4744
Advanced Health Ventures Limited
25 Belsize Crescent
London NW3 5QY
United Kingdom